Various metabolic complications are common in
the post-kidney transplant period and can negatively impact patient and graft
survival. The most important complications include post-transplant diabetes
mellitus (PTDM), dyslipidemia, metabolic syndrome, and electrolyte imbalances.
PTDM is defined as diabetes that develops after transplantation and is
evaluated regardless of the time of onset. The presence of PTDM is associated
with an increased frequency of infections, increased cardiovascular morbidity
and mortality, and an increased risk of graft loss. Dyslipidemia is
characterized by elevated levels of low-density lipoprotein cholesterol and
triglycerides, particularly in response to immunosuppressive therapies. This
contributes to the development of atherosclerotic cardiovascular disease and
facilitates the development of metabolic syndrome. Metabolic syndrome is a
complex clinical condition characterized by abdominal obesity, hypertension,
hyperglycemia, and dyslipidemia, and is a significant risk factor for
cardiovascular mortality in kidney transplant recipients. Electrolyte
imbalances are also commonly observed in the post-kidney transplant period.
Hyperkalemia, particularly due to calcineurin inhibitors reducing distal
tubular potassium secretion, can lead to serious cardiac arrhythmias.
Hypomagnesemia, on the other hand, results from multifactorial mechanisms such
as renal magnesium loss, gastrointestinal malabsorption, and immunosuppressive
drug use. Low magnesium levels increase the risk of developing PTDM through
decreased insulin secretion and increased insulin resistance, and can also
potentiate the diabetogenic effects of calcineurin inhibitors. Hypophosphatemia
is frequently seen in the early post-transplant period and is associated with
increased renal phosphate loss and persistent fibroblast growth factor-23
activity.
Atıf Sayısı :